Skip to content

CONNEXION FISUBOURSES DE FINANCEMENT DES RÉCIFSCRYPTO BTRST

Our solution

APPLICATION D'ECTOPLASME LITTLEGHOSTSAPPLICATION PNODEÉCHANGE DE BLOCKCHAIN PUBLIC GALAXIE

gate io login

ÉCHANGE ZAMAPPLICATION CLOWN PEPEAPPLICATION RICHIE

Who we are

APPLICATION SSCQ

Phase 3

APPLICATION SOMDEJ

NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial in "The Lancet Neurology Journal"

#

ÉCHANGES IBT

NeuroDerm is an agile and entrepreneurial R&D company, driving healthcare innovation and patient-centric solutions through Pharma & MedTech integration.

By developing next-generation drug-device combination solutions for central nervous system disorders, we aspire to make a meaningful difference in patients’ lives and drive future healthcare connectivity.

Our mission is to address the challenges of the future healthcare and wellbeing ecosystem. We are passionately driven to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies.

CONNEXION NUC

NeuroDerm’s flagship product ND0612 is currently in late stage development for Parkinson’s disease patients experiencing motor fluctuations. 

ND0612 integrates a proprietary pharmaceutical formulation of the gold standard levodopa/ carbidopa using state-of-the-art delivery system and digital solutions, with the aim of reducing disease burden and improving the quality of life of people with Parkinson’s disease and their families.

#

CONNEXION À KOCHI

Of gold-standard levodopa/carbidopa for continuous subcutaneous treatment

#

COINBASE NE PEUT PAS VÉRIFIER L'IDENTIFIANT

Designed to be user-friendly: Compact, portable, and self-administered

#

CONNEXION CNDL

For people with Parkinson's experiencing motor fluctuations

Find out More
#
#

RÉSEAU CALLISTO

Jun 11, 2024
#

TRAVERSER LES ÂGES SE CONNECTER

The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (hereinafter "CRL") for the New Drug Application (NDA) of investigational ND0612
Mar 18, 2024
#

ÉCHANGE DE GUILDE D'AVENTURIERS BLOCKCHAIN

Data published in The Lancet Neurology showed favorable efficacy of ND0612 compared to oral immediate-release levodopa/carbidopa
Apr 10, 2023
#

ÉCHANGES DE RÔLES

The first World Parkinson's Day (WPD) was held in 1997. The date commemorates the birthday of Dr James Parkinson, born 11 April 1755,
All News

BOURSE DE FINANCEMENT YFRX

Every person with a Parkinson's diagnosis has his or her own unpredictable journey. By educating yourself about Parkinson’s and the new emerging therapies as well as becoming a true expert on your personal Parkinson’s you can regain control over your life again. We hope that this website will accompany you and support you on this journey.

#
#

CONNEXION GALTCOIN

For general inquiries or to learn more about NeuroDerm, please complete the form below. For medical information or to report on your own health or experience, please consult your healthcare provider. Please click here for information about our clinical trials.

*
*
*
*